SLU-PP-332
Estrogen-related receptor (ERR) agonist · listed as “SLUPP-332”
Small-molecule ERR agonist (not a peptide) studied as an exercise mimetic in mice only.
Not FDA-approved. Preclinical research compound only. No human trials. This page describes research and public discussion; it is not a recommendation to use.
Overview
SLU-PP-332 is a synthetic small molecule from Saint Louis University. In mice it increased endurance and fat oxidation and reduced weight gain. It has never been tested in humans.
Mechanism of action
Pan-agonist of estrogen-related receptors (ERRα/β/γ), increasing mitochondrial biogenesis and oxidative muscle fiber programming.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
No human data C Preliminary research No controlled human dosing data exist for this indication. | Not established | — | — | — |
Clinical trials & studies
- Animal2024A synthetic ERR agonist alleviates metabolic syndrome (JPET)
Reduced fat mass and improved insulin sensitivity in obese mice.
Safety
Side effects
- Unknown in humans
Contraindications
- Pregnancy
- Any use outside research
Interactions
- Unknown
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Preclinical research compound only. No human trials.
FAQ
Considering a GLP-1 for weight loss?
Compare licensed telehealth providers by true monthly cost and care quality.
See your top 3 matches